| 0.096 0.003 (3.17%) | 12-29 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Aptinyx Inc. is a biopharmaceutical company in the clinical development stage, focused on identifying, advancing, and commercializing innovative, proprietary, synthetic small-molecule therapies for neurological and central nervous system disorders. Its primary drug candidate, NYX-2925, is currently in Phase II clinical trials for addressing painful diabetic peripheral neuropathy, and also in Phase IIb evaluation for fibromyalgia. Additionally, the company is developing NYX-783, an N-methyl-D-aspartate receptor (NMDAr) modulator, which is undergoing Phase IIb clinical trials for post-traumatic stress disorder (PTSD). Another NMDAr modulator, NYX-458, is in Phase II clinical study, targeting cognitive impairment related to Parkinson's disease. Aptinyx Inc. also holds a research collaboration agreement with Allergan plc. The company was founded in 2015 and is based in Evanston, Illinois.
Mon, 18 Dec 2023
Aptinyx Inc. Approves Liquidating Cash Distribution, Payable on or About December 29, 2023 - marketscreener.com
Sun, 27 Nov 2022
David Houck Net Worth (2026) - GuruFocus
Sat, 27 Aug 2022
What is the current Price Target and Forecast for (APTX) - Zacks Investment Research
Mon, 25 Jun 2018
Aptinyx Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - PR Newswire
Mon, 22 Feb 2016
Will Cyclobenzaprine Be A Solution For Fibromyalgia Patients? - Clinical Leader
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|